Ventas, Inc. (VTR)
Data as of August 11, 2026 · REIT - Healthcare Facilities
Stockbruh grade: Strong 4/5 metrics rated Sunny
What does Ventas, Inc. do?
Ventas, the powerhouse at the intersection of healthcare and real estate, is unlocking the value of properties worldwide. Headquartered in the bustling S&P 500, Ventas partners with top care providers, developers, and healthcare organizations to ride the wave of an aging population. With a diverse portfolio, experienced team, and strong balance sheet, Ventas is all about consistent cash flows and superior returns. Together, we're building a future where healthcare meets real estate 🏥🏢.
Key Numbers
| Metric | Rating | What it means |
|---|
| Returns (5Y) | ☀️ Strong | 5-year price performance |
| Profitability | ☀️ Strong | Net margin & return on equity |
| Growth | ☀️ Strong | Revenue & earnings trend |
| Earnings | ☀️ Strong | EPS vs analyst expectations |
| Cash & Debt | ⛈️ Weak | Balance sheet strength |
| Price | $91.91 | Market Cap | — |
| Exchange | New York Stock Exchange | | |
Plain-English Analysis
What's it worth?
Based on 5-year performance trends, Ventas, Inc. has historically delivered strong returns. Sign up free for full valuation analysis including P/E, DCF estimates, and Stockbruh's plain-English take on whether this stock looks cheap or expensive right now.
How the business works
Ventas, the powerhouse at the intersection of healthcare and real estate, is unlocking the value of properties worldwide. Headquartered in the bustling S&P 500, Ventas partners with top care providers, developers, and healthcare organizations to ride the wave of an aging population. Sign up free for competitor and revenue breakdown ↗
Are they building the future?
Revenue and earnings are trending upward — Ventas, Inc. appears to be growing. Sign up free for the full growth analysis including year-over-year comparisons and R&D investment data.
What's ahead?
Recent earnings have been strong, meeting or beating analyst expectations. Sign up free for earnings history, EPS trends, and what analysts are forecasting next.